TrialNCT07218146
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- Status
- RECRUITING
- Phase
- PHASE3
- Last update posted
- 09/04/2026
- Start
- 11/30/2025
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Specialties
- oncology
Conditions: Small-cell Lung Cancer
Brief summary
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
Protocol documents and results are not hosted here. Verify every detail on ClinicalTrials.gov.